{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T02:40:48Z","timestamp":1784256048519,"version":"3.55.0"},"reference-count":5,"publisher":"Georg Thieme Verlag KG","issue":"07","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Gesundheitswesen"],"published-print":{"date-parts":[[2023,7]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>\n          Hintergrund Geb\u00e4rmutterhalskrebs ist weltweit ein\n                    ma\u00dfgebliches Gesundheitsproblem. Screenings zur\n                    Sekund\u00e4rpr\u00e4vention haben das Ziel, Morbidit\u00e4t und\n                    Mortalit\u00e4t zu senken. Ziel\u2002Die Leitlinie bietet einen\n                    aktualisierten und erweiterten \u00dcberblick zur Pr\u00e4vention von\n                    Geb\u00e4rmutterhalskrebs durch Screening und Therapie.<\/jats:p><jats:p>\n          Methode Die Weltgesundheitsorganisation (WHO) erarbeitete diese Leitlinie\n                    gem\u00e4\u00df WHO-Standards. Ein Team des WHO Collaborating Centre an\n                    der Universit\u00e4t f\u00fcr Weiterbildung Krems (\u00d6sterreich) hat\n                    die Zusammenfassung der zweiten Auflage aus dem Englischen\n                    \u00fcbersetzt.<\/jats:p><jats:p>\n          Ergebnisse Die aktualisierte und erweiterte Leitlinie enth\u00e4lt 23\n                    Empfehlungen und sieben Good-Practice-Statements \u2013 diese beziehen sich\n                    u.\u2009a. auf Screeningmethoden, Testabfolge, Altersgruppen und Intervalle.\n                    Eine von zwei angesprochenen Zielgruppen sind Frauen aus der\n                    Allgemeinbev\u00f6lkerung ohne bekanntes Risiko \u2013 diese Population\n                    soll ab einem Alter von 30 Jahren alle f\u00fcnf bis zehn Jahre gescreent\n                    werden. Zweite Zielgruppe sind HIV-positive Frauen, f\u00fcr die Screenings\n                    ab einem Alter von 25 Jahren im Abstand von drei bis f\u00fcnf Jahren\n                    angeboten werden sollen. Als Prim\u00e4rscreening sind in erster Linie\n                    HPV-DNA-Tests empfohlen, ggf. erg\u00e4nzt durch einen weiteren Test im\n                    Rahmen einer Triage, um \u00fcber weitere Interventionen zu entscheiden.<\/jats:p>","DOI":"10.1055\/a-2052-6652","type":"journal-article","created":{"date-parts":[[2023,7,12]],"date-time":"2023-07-12T22:30:34Z","timestamp":1689201034000},"page":"630-634","source":"Crossref","is-referenced-by-count":9,"title":["WHO-Leitlinie zu Screening und Behandlung von\n                    pr\u00e4kanzer\u00f6sen Zervixl\u00e4sionen f\u00fcr die\n                    Pr\u00e4vention von Geb\u00e4rmutterhalskrebs (2. Auflage)"],"prefix":"10.1055","volume":"85","author":[{"given":"Julia","family":"Harlfinger","sequence":"additional","affiliation":[{"name":"Department f\u00fcr Evidenzbasierte Medizin und Klinische\n                    Epidemiologie, Donau-Universitat Krems Department f\u00fcr Evidenzbasierte\n                    Medizin und Evaluation, Krems, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3592-1507","authenticated-orcid":false,"given":"Isolde","family":"Sommer","sequence":"additional","affiliation":[{"name":"Cochrane \u00d6sterreich, Department f\u00fcr Evidenzbasierte\n                    Medizin und Evaluation, Universit\u00e4t f\u00fcr Weiterbildung Krems,\n                    Krems an der Donau, Austria"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Gartlehner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2023,7,12]]},"reference":[{"key":"ref1","volume-title":"WHO guideline for screening and treatment of cervical pre-cancer lesions for\n                    cervical cancer prevention, second edition","year":"2021"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality\n                    worldwide for 36 cancers in 185 countries","volume":"71","author":"H Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"ref4","volume-title":"WHO handbook for guideline development, second edition","year":"2014"},{"key":"ref5","volume-title":"WHO guidelines for screening and treatment of precancerous lesions for cervical\n                    cancer prevention","year":"2013"},{"key":"ref6","volume-title":"IARC handbooks of cancer prevention: Cervical Cancer Screening, Vol. 18","author":"International Agency for Research on\n                        Cancer","year":"2022"}],"container-title":["Das Gesundheitswesen"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2052-6652.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T00:35:12Z","timestamp":1719621312000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2052-6652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":5,"journal-issue":{"issue":"07","published-online":{"date-parts":[[2023,7,12]]},"published-print":{"date-parts":[[2023,7]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2052-6652","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0941-3790","1439-4421"],"issn-type":[{"value":"0941-3790","type":"print"},{"value":"1439-4421","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]}}}